The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Targeted protein degradation: A promise for undruggable proteins
Open accessAbstract
SUMMARY Protein homeostasis, or “proteostasis”, is indispensable for a balanced, healthy environment within the cell. However, when natural proteostasis mechanisms are overwhelmed from excessive loads of dysregulated proteins, their accumulation can lead to disease initiation and progression. Fortunately, the induced degradation of such disease-causing proteins by heterobifunctional molecules, i.e., PROteolysis TArgeting Chimeras (PROTACs), is emerging as a potential therapeutic modality. In the two decades since the PROTAC concept was proposed, several additional Targeted Protein Degradation (TPD) strategies have also been explored to target previously undruggable proteins, such as transcription factors. In this review, we will discuss the progress and evolution of the TPD field, the breadth of the proteins targeted by PROTACs and the biological effects of their degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Self-citationThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
FAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction.
Takeshige, K., Baba, M., Tsuboi, S., Noda, T., & Ohsumi, Y. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.2.301 · Cited by 1,264
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Self-citationGenome Engineering With Zinc-Finger Nucleases
Carroll, D. (2011) · Genetics · doi:10.1534/genetics.111.131433 · Cited by 1,076
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Nurgali, K., Jagoe, R. T., & Abalo, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00245 · Cited by 1,017
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Self-citationDrugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923
Self-citationCellular strategies for controlling protein aggregation
Tyedmers, J., Mogk, A., & Bukau, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2993 · Cited by 896
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Self-citationThe ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A. S., Michellys, P.-Y., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 840
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Self-citationProtein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Self-citationModular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
Self-citationTargeted Cancer Therapy: The Next Generation of Cancer Treatment
Baudino, T. (2015) · Current Drug Discovery Technologies · doi:10.2174/1570163812666150602144310 · Cited by 611
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Self-citationEpigenetic modifications of histones in cancer
Zhao, Z., & Shilatifard, A. (2019) · Genome Biology · doi:10.1186/s13059-019-1870-5 · Cited by 552
Multiplexed CRISPR technologies for gene editing and transcriptional regulation
McCarty, N. S., Graham, A. E., Studená, L., & Ledesma-Amaro, R. (2020) · Nature Communications · doi:10.1038/s41467-020-15053-x · Cited by 552
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517
Self-citationAn enhanced CRISPR repressor for targeted mammalian gene regulation
Yeo, N. C., Chavez, A., Lance-Byrne, A., Chan, Y., Menn, D., Milanova, D., Kuo, C.-C., Guo, X., Sharma, S., Tung, A., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0048-5 · Cited by 496
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 490
Self-citationChemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 487
Self-citationRole of p38 MAP Kinase Signal Transduction in Solid Tumors
Koul, H. K., Pal, M., & Koul, S. (2013) · Genes & Cancer · doi:10.1177/1947601913507951 · Cited by 484
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476
Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
Self-citationAurora A kinase (AURKA) in normal and pathological cell division
Nikonova, A. S., Astsaturov, I., Serebriiskii, I. G., Dunbrack, R. L., & Golemis, E. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1073-7 · Cited by 448
ortho‐Fluoroazobenzenes: Visible Light Switches with Very Long‐Lived Z Isomers
Knie, C., Utecht, M., Zhao, F., Kulla, H., Kovalenko, S., Brouwer, A. M., Saalfrank, P., Hecht, S., & Bléger, D. (2014) · Chemistry – A European Journal · doi:10.1002/chem.201404649 · Cited by 438
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Huang, H.-T., Dobrovolsky, D., Paulk, J., Yang, G., Weisberg, E. L., Doctor, Z. M., Buckley, D. L., Cho, J.-H., Ko, E., Jang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.10.005 · Cited by 437
5-fluorouracil and cardiotoxicity: a review
Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918780140 · Cited by 433
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., & Deshaies, R. J. (2003) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t300009-mcp200 · Cited by 425
Self-citationCurrent strategies for the design of PROTAC linkers: a critical review
Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413
STAT3 SIGNALING: Anticancer Strategies and Challenges
Johnston, P. A., & Grandis, J. R. (2011) · Molecular Interventions · doi:10.1124/mi.11.1.4 · Cited by 406
Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394
Self-citationLight-Induced Protein Degradation with Photocaged PROTACs
Xue, G., Wang, K., Zhou, D., Zhong, H., & Pan, Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06422 · Cited by 377
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Visconti, R., Della Monica, R., & Grieco, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0433-9 · Cited by 366
Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00285 · Cited by 350
Salami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349
Self-citationHines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2918 · Cited by 348
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Ahn, I. E., Underbayev, C., Albitar, A., Herman, S. E. M., Tian, X., Maric, I., Arthur, D. C., Wake, L., Pittaluga, S., Yuan, C. M., et al. (2017) · Blood · doi:10.1182/blood-2016-06-719294 · Cited by 341
PHOTACs enable optical control of protein degradation
Reynders, M., Matsuura, B. S., Bérouti, M., Simoneschi, D., Marzio, A., Pagano, M., & Trauner, D. (2020) · Science Advances · doi:10.1126/sciadv.aay5064 · Cited by 321
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Pfaff, P., Samarasinghe, K. T. G., Crews, C. M., & Carreira, E. M. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00713 · Cited by 301
Self-citationCRISPR/Cas9-based engineering of the epigenome
Pulecio, J., Verma, N., Mejía-Ramírez, E., Huangfu, D., & Raya, A. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.09.006 · Cited by 300
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293
Light-induced control of protein destruction by opto-PROTAC
Liu, J., Chen, H., Ma, L., He, Z., Wang, D., Liu, Y., Lin, Q., Zhang, T., Gray, N., Kaniskan, H. Ü., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5154 · Cited by 292
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Rickert, R. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3487 · Cited by 288
He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15838-0 · Cited by 280
Waste disposal—An attractive strategy for cancer therapy
Salami, J., & Crews, C. M. (2017) · Science · doi:10.1126/science.aam7340 · Cited by 279
Self-citationInteraction of an NF-kappa B-like factor with a site upstream of the c-myc promoter.
Duyao, M. P., Buckler, A. J., & Sonenshein, G. E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4727 · Cited by 278
Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies
Lovly, C. M., & Shaw, A. T. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1610 · Cited by 273
Development of dual and selective degraders of cyclin-dependent kinases 4 and 6
Jiang, B., Wang, E. S., Donovan, K. A., Liang, Y., Fischer, E. S., Zhang, T., & Gray, N. S. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901336 · Cited by 272
Small-molecule-induced polymerization triggers degradation of BCL6
Słabicki, M., Yoon, H., Koeppel, J., Nitsch, L., Roy Burman, S. S., Di Genua, C., Donovan, K. A., Sperling, A. S., Hunkeler, M., Tsai, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2925-1 · Cited by 270
The pathways to tumor suppression via route p38
Han, J., & Sun, P. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.06.007 · Cited by 267
Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Oláh, J., Ovádi, J., Sippl, W., & Jung, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01872 · Cited by 263
Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00635 · Cited by 257
Self-citationPROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene · doi:10.1038/s41388-020-1336-y · Cited by 252
Bainton, D. F. (1981) · The Journal of cell biology · doi:10.1083/jcb.91.3.66s · Cited by 231
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.071 · Cited by 226
PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes
Zaidman, D., Prilusky, J., & London, N. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00589 · Cited by 224
Bond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 221
Self-citationWoyach, J. A., Bojnik, E., Ruppert, A. S., Stefanovski, M. R., Goettl, V. M., Smucker, K. A., Smith, L. L., Dubovsky, J. A., Towns, W. H., MacMurray, J., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515361 · Cited by 220
Optical Control of Small Molecule-Induced Protein Degradation
Naro, Y., Darrah, K., & Deiters, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12718 · Cited by 218
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
Burslem, G. M., Schultz, A. R., Bondeson, D. P., Eide, C. A., Savage Stevens, S. L., Druker, B. J., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1236 · Cited by 212
Self-citationChemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C. M., Deshaies, R. J., & Sakamoto, K. M. (2008) · Oncogene · doi:10.1038/onc.2008.320 · Cited by 206
Self-citationRecent advances in the CRISPR genome editing tool set
Moon, S. B., Kim, D. Y., Ko, J.-H., & Kim, Y.-S. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0339-7 · Cited by 203
Mutation Hotspots in the β-Catenin Gene: Lessons from the Human Cancer Genome Databases.
Kim, S., & Jeong-Yu, S. (2019) · PubMed Central · doi:10.14348/molcells.2018.0436 · Cited by 203
EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex
Hsu, J. H.-R., Rasmusson, T., Robinson, J., Pachl, F., Read, J., Kawatkar, S., O’ Donovan, D. H., Bagal, S., Code, E., Rawlins, P., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.11.004 · Cited by 202
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Powell, C. E., Gao, Y., Tan, L., Donovan, K. A., Nowak, R. P., Loehr, A., Bahcall, M., Fischer, E. S., Jänne, P. A., George, R. E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01655 · Cited by 198
The secret life of kinases: functions beyond catalysis
Rauch, J., Volinsky, N., Romano, D., & Kolch, W. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-23 · Cited by 196
Cuneo, K. C., Morgan, M. A., Sahai, V., Schipper, M. J., Parsels, L. A., Parsels, J. D., Devasia, T., Al-Hawaray, M., Cho, C. S., Nathan, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00730 · Cited by 195
ALK: a tyrosine kinase target for cancer therapy
Holla, V. R., Elamin, Y. Y., Bailey, A. M., Johnson, A. M., Litzenburger, B. C., Khotskaya, Y. B., Sanchez, N. S., Zeng, J., Shufean, M. A., Shaw, K. R., et al. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001115 · Cited by 192
The Stress Kinase p38α as a Target for Cancer Therapy
Igea, A., & Nebreda, A. R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0173 · Cited by 189
Cheng, M., Yu, X., Lu, K., Xie, L., Wang, L., Meng, F., Han, X., Chen, X., Liu, J., Xiong, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01566 · Cited by 189
Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach
Bassi, Z. I., Fillmore, M. C., Miah, A. H., Chapman, T. D., Maller, C., Roberts, E. J., Davis, L. C., Lewis, D. E., Galwey, N. W., Waddington, K. E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00705 · Cited by 186
Costales, M. G., Aikawa, H., Li, Y., Childs-Disney, J. L., Abegg, D., Hoch, D. G., Pradeep Velagapudi, S., Nakai, Y., Khan, T., Wang, K. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914286117 · Cited by 185
Principles and mechanisms of non-genetic resistance in cancer
Bell, C. C., & Gilan, O. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0648-6 · Cited by 182
Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras
Samarasinghe, K. T. G., Jaime-Figueroa, S., Burgess, M., Nalawansha, D. A., Dai, K., Hu, Z., Bebenek, A., Holley, S. A., & Crews, C. M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.011 · Cited by 182
Self-citationThe Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target
Cardenas, M. G., Oswald, E., Yu, W., Xue, F., MacKerell, A. D., & Melnick, A. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2071 · Cited by 180
Systematic approaches to identify E3 ligase substrates
Iconomou, M., & Saunders, D. N. (2016) · Biochemical Journal · doi:10.1042/bcj20160719 · Cited by 178
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown
Jin, Y.-H., Lu, M.-C., Wang, Y., Shan, W.-X., Wang, X.-Y., You, Q.-D., & Jiang, Z.-Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02058 · Cited by 178
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300
Vannam, R., Sayilgan, J., Ojeda, S., Karakyriakou, B., Hu, E., Kreuzer, J., Morris, R., Herrera Lopez, X. I., Rai, S., Haas, W., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.12.004 · Cited by 177
Burslem, G. M., Song, J., Chen, X., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10320 · Cited by 176
Self-citationRewiring cell polarity signaling in cancer
Halaoui, R., & McCaffrey, L. (2015) · Oncogene · doi:10.1038/onc.2014.59 · Cited by 174
Hines, J., Gough, J. D., Corson, T. W., & Crews, C. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217206110 · Cited by 172
Self-citationMechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171
BCL2 mutations in diffuse large B-cell lymphoma
Schuetz, J. M., Johnson, N. A., Morin, R. D., Scott, D. W., Tan, K. X., Neriah, S. B., Boyle, M., Slack, G. W., Marra, M. A., Connors, J. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.378 · Cited by 171
PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
Adhikari, B., Bozilovic, J., Diebold, M., Schwarz, J. D., Hofstetter, J., Schröder, M., Wanior, M., Narain, A., Vogt, M., Dudvarski Stankovic, N., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00652-y · Cited by 171
Petrylak, D. P., Gao, X., Vogelzang, N. J., Garfield, M. H., Taylor, I., Dougan Moore, M., Peck, R. A., & Burris, H. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3500 · Cited by 169
Is β-Catenin a Druggable Target for Cancer Therapy?
Cui, C., Zhou, X., Zhang, W., Qu, Y., & Ke, X. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.06.003 · Cited by 168
Hwang, S.-Y., Deng, X., Byun, S., Lee, C., Lee, S.-J., Suh, H., Zhang, J., Kang, Q., Zhang, T., Westover, K. D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.071 · Cited by 164
Dysfunction of Cellular Proteostasis in Parkinson’s Disease
Lehtonen, Š., Sonninen, T.-M., Wojciechowski, S., Goldsteins, G., & Koıstınaho, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00457 · Cited by 163
Nature and Regulation of Protein Folding on the Ribosome
Waudby, C. A., Dobson, C. M., & Christodoulou, J. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.06.008 · Cited by 161
Yang, J., McDowell, A., Kim, E. K., Seo, H., Lee, W. H., Moon, C. M., Kym, S.-M., Lee, D. H., Park, Y. S., Jee, Y., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0313-4 · Cited by 157
Liao, H., Li, X., Zhao, L., Wang, Y., Wang, X., Wu, Y., Zhou, X., Fu, W., Liu, L., Hu, H.-G., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-0171-1 · Cited by 156
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Self-citationTargeting the Undruggable Proteome: The Small Molecules of My Dreams
Crews, C. M. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.011 · Cited by 147
Self-citationSTAT3 inhibitors for cancer therapy: Have all roads been explored?
Fagard, R., Metelev, V., Souissi, I., & Baran‐Marszak, F. (2013) · JAK-STAT · doi:10.4161/jkst.22882 · Cited by 146
Cyclin/cdk complexes: Their involvement in cell cycle progression and mitotic division
John, P. C. L., Mews, M., & Moore, R. H. (2001) · PROTOPLASMA · doi:10.1007/bf02673865 · Cited by 144
A caged E3 ligase ligand for PROTAC-mediated protein degradation with light
Kounde, C. S., Shchepinova, M. M., Saunders, C. N., Muelbaier, M., Rackham, M. D., Harling, J. D., & Tate, E. W. (2020) · Chemical Communications · doi:10.1039/d0cc00523a · Cited by 144
Functional characterization of a PROTAC directed against BRAF mutant V600E
Posternak, G., Tang, X., Maisonneuve, P., Jin, T., Lavoie, H., Daou, S., Orlicky, S. M., de Rugy, T. G., Caldwell, L., Chan, K., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0609-7 · Cited by 140
McCoull, W., Cheung, T., Anderson, E., Barton, P., Burgess, J., Byth, K., Cao, Q., Castaldi, M. P., Chen, H., Chiarparin, E., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00698 · Cited by 139
Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
Flanagan, J., Qian, Y., Gough, S. M., Andreoli, M., Bookbinder, M., Cadelina, G. W., Bradley, J., Rousseau, E., Willard, R. R., Pizzano, J., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p5-04-18 · Cited by 139
Self-citationDT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00928-9 · Cited by 139
An ancient divergence among the bacteria
Balch, W. E., Magrum, L. J., Fox, G. E., WOLFE, R. S., & Woese, C. R. (1977) · Journal of Molecular Evolution · doi:10.1007/bf01796092 · Cited by 134
Developing potent PROTACs tools for selective degradation of HDAC6 protein
An, Z., Lv, W., Su, S., Wu, W., & Rao, Y. (2019) · Protein & Cell · doi:10.1007/s13238-018-0602-z · Cited by 133
Zhang, H., Zhao, H., Xi, X.-X., Liu, Y., Xin, M., Mao, S., Zhang, J., Lu, A., & Zhang, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112061 · Cited by 133
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Xiao, Y., Wang, J., Zhao, L., Chen, X., Zheng, G., Zhang, X., & Liao, D. (2020) · Chemical Communications · doi:10.1039/d0cc03243c · Cited by 132
Kang, C. H., Lee, D.-H., Lee, C. O., Ha, J. D., Park, C. H., & Hwang, J. Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.169 · Cited by 131
PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer
Zhao, B., & Burgess, K. (2019) · Chemical Communications · doi:10.1039/c9cc00163h · Cited by 131
Baker, E. K., Taylor, S., Gupte, A., Sharp, P. P., Walia, M., Walsh, N. C., Zannettino, A. C. W., Chalk, A. M., Burns, C. J., & Walkley, C. R. (2015) · Scientific Reports · doi:10.1038/srep10120 · Cited by 130
Estrogen Receptors: Role in Breast Cancer
Duffy, M. J. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360600739218 · Cited by 122
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
Smalley, J. P., Adams, G. E., Millard, C. J., Song, Y., Norris, J. K. S., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2020) · Chemical Communications · doi:10.1039/d0cc01485k · Cited by 121
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
Development of selective mono or dual PROTAC degrader probe of CDK isoforms
Zhou, F., Chen, L., Cao, C.-G., Yu, J., Luo, X., Zhou, P., Zhao, L., Du, W., Cheng, J., Xie, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111952 · Cited by 121
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Dragovich, P. S., Adhikari, P., Blake, R. A., Blaquiere, N., Chen, J., Cheng, Y.-X., den Besten, W., Han, J., Hartman, S. J., He, J., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126907 · Cited by 120
Wang, Z., He, N., Guo, Z., Niu, C., Song, T., Guo, Y., Cao, K., Wang, A., Zhu, J., Zhang, X., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00919 · Cited by 120
Transcription factor decoy technology: A therapeutic update
Hecker, M., & Wagner, A. H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.122 · Cited by 118
Design and synthesis of selective degraders of EGFRL858R/T790M mutant
Zhang, X., Xu, F., Tong, L., Zhang, T., Xie, H., Lu, X., Ren, X., & Ding, K. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112199 · Cited by 114
Development and Characterization of a Wee1 Kinase Degrader
Li, Z., Pinch, B. J., Olson, C. M., Donovan, K. A., Nowak, R. P., Mills, C. E., Scott, D. A., Doctor, Z. M., Eleuteri, N. A., Chung, M., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.10.013 · Cited by 111
Protein degradation through covalent inhibitor-based PROTACs
Xue, G., Chen, J., Liu, L., Zhou, D., Zuo, Y., Fu, T., & Pan, Z. (2020) · Chemical Communications · doi:10.1039/c9cc08238g · Cited by 111
Phthalimide conjugations for the degradation of oncogenic PI3K
Li, W., Gao, C., Zhao, L., Yuan, Z., Chen, Y., & Jiang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.066 · Cited by 109
Discovery of potent small molecule PROTACs targeting mutant EGFR
Zhao, H., Yang, X., Lei, H., Xi, X.-X., Lu, S., Zhang, J., Xin, M., & Zhang, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112781 · Cited by 108
The activities and function of molecular chaperones in the endoplasmic reticulum
Buck, T. M., Wright, C. M., & Brodsky, J. L. (2007) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2007.09.001 · Cited by 107
Shimokawa, K., Shibata, N., Sameshima, T., Miyamoto, N., Ujikawa, O., Nara, H., Ohoka, N., Hattori, T., Cho, N., & Naito, M. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00247 · Cited by 104
Bensimon, A., Pizzagalli, M. D., Kartnig, F., Dvorak, V., Essletzbichler, P., Winter, G. E., & Superti-Furga, G. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.04.003 · Cited by 102
Engel, J., Lategahn, J., & Rauh, D. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00475 · Cited by 101
Lee, G. T., Nagaya, N., Desantis, J., Madura, K., Sabaawy, H. E., Kim, W.-J., Vaz, R. J., Cruciani, G., & Kim, I. Y. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0417 · Cited by 98
Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
Tovell, H., Testa, A., Zhou, H., Shpiro, N., Crafter, C., Ciulli, A., & Alessi, D. R. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00505 · Cited by 96
Nuclear autophagy: An evolutionarily conserved mechanism of nuclear degradation in the cytoplasm
Luo, M., Zhao, X., Song, Y., Cheng, H., & Zhou, R. (2016) · Autophagy · doi:10.1080/15548627.2016.1217381 · Cited by 94
BCL-2 is dispensable for thrombopoiesis and platelet survival
Debrincat, M. A., Pleines, I., Lebois, M., Lane, R. M., Holmes, M. L., Corbin, J., Vandenberg, C. J., Alexander, W. S., Ng, A. P., Strasser, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.97 · Cited by 92
Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86
Fan, H., Zhao, X., Sun, S., Luo, M., & Guan, J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.420497 · Cited by 85
Sun, N., Ren, C., Kong, Y., Zhong, H., Chen, J., Li, Y., Zhang, J., Zhou, Y., Qiu, X., Lin, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112190 · Cited by 85
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00147 · Cited by 77
Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
Wang, Q., Pechersky, Y., Sagawa, S., Pan, A. C., & Shaw, D. E. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819301116 · Cited by 76
Roberts, B. L., Ma, Z., Gao, A., Leisten, E. D., Yin, D., Xu, W., & Tang, W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00140 · Cited by 75
Yang, C., Cao, P., Gao, Y., Wu, M., Lin, Y., Tian, Y., & Yuan, W. (2016) · Scientific Reports · doi:10.1038/srep22182 · Cited by 69
Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis
Osuna, M. Á. L., García-López, J., Ayachi, I. E., Fatima, I., Khalid, A. B., Kumpati, J., Slayden, A. V., Seagroves, T. N., Miranda‐Carboni, G. A., & Krum, S. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1255 · Cited by 69
Williams, K. M., Qie, S., Atkison, J. H., Salazar-Arango, S., Diehl, J. A., & Olsen, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-11061-8 · Cited by 68
He, K., Zhang, Z., Wang, W., Zheng, X., Wang, X., & Zhang, X. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127167 · Cited by 66
Pontoriero, M., Fiume, G., Vecchio, E., de Laurentiis, A., Albano, F., Iaccino, E., Mimmi, S., Pisano, A., Agosti, V., Giovannone, E. D., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01777-x · Cited by 59
Effects of pH and Salt Concentration on Stability of a Protein G Variant Using Coarse-Grained Models
de Oliveira, V. M., Contessoto, V. G., da Silva, F. B., Caetano, D. L. Z., de Carvalho, S. J., & Leite, V. B. P. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.11.012 · Cited by 58
Lønning, P. E., & Knappskog, S. (2013) · Oncogene · doi:10.1038/onc.2013.48 · Cited by 57
Li, Z., Lin, Y., Song, H., Qin, X., Yu, Z., Zhang, Z., Dong, G., Li, X., Shi, X., Du, L., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.014 · Cited by 55
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Shibata, N., Shimokawa, K., Nagai, K., Ohoka, N., Hattori, T., Miyamoto, N., Ujikawa, O., Sameshima, T., Nara, H., Cho, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31913-5 · Cited by 54
Kojima, Y., Sasaki, S., Shinoura, H., Hayashi, Y., Tsujimoto, G., & Kohri, K. (2006) · The Prostate · doi:10.1002/pros.20399 · Cited by 53
Chen, H., Chen, F., Liu, N., Wang, X., & Gou, S. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.005 · Cited by 51
Hu, J., Wei, J., Yim, H., Wang, L., Xie, L., Jin, M. S., Kabir, M., Qin, L., Chen, X., Liu, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01609 · Cited by 43
The Development of TALE Nucleases for Biotechnology
Ousterout, D. G., & Gersbach, C. A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2932-0_3 · Cited by 43
Expanding Proteostasis by Membrane Trafficking Networks
Hutt, D. M., & Balch, W. E. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a013383 · Cited by 40
Tang, Y., Han, B., Xin-quan, Y., Hong, Y., Wang, Y., Zhao, F., Yu, S., Sun, X., & Xia, S. (2008) · Asian Journal of Andrology · doi:10.1038/aja.2008.26 · Cited by 38
Sammak, S., & Zinzalla, G. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.06.004 · Cited by 37
Li, Y., Li, X., Pu, J., Yang, Q., Guan, H., Ji, M., Shi, B., Chen, M., & Hou, P. (2018) · Thyroid · doi:10.1089/thy.2018.0183 · Cited by 33
Bi, S., Wei, Q., Zhao, Z., Chen, L., Wang, C., & Xie, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00864 · Cited by 20
Kuang, P., Chen, Z., Wang, J., Liu, Z., Wang, J., Gao, J., & Shen, L. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.02.010 · Cited by 14
Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin
Verheul, T. C. J., Trinh, V. T., Vázquez, O., & Philipsen, S. (2020) · ChemMedChem · doi:10.1002/cmdc.202000574 · Cited by 14
Modeling the therapeutic efficacy of NFκB synthetic decoy oligodeoxynucleotides (ODNs)
Wang, Z., Potoyan, D. A., & Wolynes, P. G. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0525-6 · Cited by 8
STAT3 cyclic oligonucleotide decoy—a new therapeutic avenue for NSCLC?
Lee, L. Y. W., Mohammad, S., Starkey, T., & Lee, S. M. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.14 · Cited by 4
Cited by
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
PROTAC degraders as chemical probes for studying target biology and target validation
Němec, V., Schwalm, M. P., Müller, S., & Knapp, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00478j · Cited by 98
Translational PK–PD for targeted protein degradation
Bartlett, D. W., & Gilbert, A. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00114d · Cited by 55
Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Shu, C., Zhang, B., Zeng, Z., Gu, S., Zhang, Y., et al. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.008 · Cited by 51
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., & Han, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01712 · Cited by 46
Metadata
- Authors
- Samarasinghe, K. T. G., & Crews, C. M.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 28
- Issue
- 7
- Pages
- 934-951
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W3161698207
- Cited by
- 271
- References
- 181
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.